Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily administered 0.5% Timolol Ophthalmic Solution concurrently in patients with open-angle glaucoma or ocular hypertension

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Diagnosis of open-angle glaucoma or ocular hypertension in one or both eyes

• Eye pressure lowering topical medications are not working

• Visual acuity is at least 0.2 in each eye

Exclusion Criteria:

• Uncontrolled systemic disease

• Any other active eye disease other than glaucoma or ocular hypertension

• Significant visual field loss or evidence of progressive visual field loss within the last year

• Anticipated wearing of contact lenses during the study

• Required chronic use of other ocular medications during the study

• Eye surgery or laser treatment within 12 weeks prior to study enrollment